Life Sciences Times, Author at Boston Life Sciences Times

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

December 11, 2025

Study Links Tumor Metabolism to Drug Binding Behavior in Live Cancer Cells

December 9, 2025

Entrepreneur of the Year Award Honors Dermatology Innovator Reid Waldman, M.D.

December 8, 2025

THIS WEEK'S STORIES

Phare Bio and Basilea form partnership to develop AI-designed broad-spectrum antibiotic

December 11, 2025

Zai Lab Begins Global Phase 1/1b Trial of ZL-1503 for Atopic Dermatitis

December 8, 2025

Ventus Therapeutics announces first patient dosed in Phase 2 trial of VENT-03 for lupus

December 10, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

Sunoh.ai joins athenahealth Marketplace to expand access to AI-driven clinical documentation

Phare Bio and Basilea form partnership to develop AI-designed broad-spectrum antibiotic

Suffolk hires Roger Moore to strengthen healthcare construction leadership in California

Survey shows healthcare experts fear AI will accelerate online medical misinformation

EDITOR PICKS

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

Study Links Tumor Metabolism to Drug Binding Behavior in Live Cancer Cells

Entrepreneur of the Year Award Honors Dermatology Innovator Reid Waldman, M.D.

THIS WEEK'S STORIES

Phare Bio and Basilea form partnership to develop AI-designed broad-spectrum antibiotic

Zai Lab Begins Global Phase 1/1b Trial of ZL-1503 for Atopic Dermatitis

Ventus Therapeutics announces first patient dosed in Phase 2 trial of VENT-03 for lupus

POPULAR CATEGORY

ABOUT US

FOLLOW US